Stem cell therapy for heart failure: The science and current progress

Future Cardiology

Volumn 4, Issue 3, 2008, Pages 285-298

  Phillips, M Ian ^a   Tang, Yao Liang ^a   Pinkernell, Kai ^b  

^a KECK GRADUATE INSTITUTE   (United States)

^b Cytori Therapeutics Inc   (United States)

Author keywords

Adipose derived; Akt; Cardiac derived; Cell therapy; Genetic modification; Heme oxygenase; Human embryonic stem cells; Induced pluripotency; Ischemic heart disease; Myoblasts; Stem cells; Umbilical cord blood cells

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHEMOKINE RECEPTOR CXCR4; DIGOXIN; HEME OXYGENASE; MYOSIN LIGHT CHAIN 2; PLACEBO; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX2.5;

ADIPOSE TISSUE CELL; CARDIOMYOPATHY; CELL DEGENERATION; CELL HYPOXIA; CELL SURVIVAL; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; DEFIBRILLATOR; DNA MODIFICATION; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEART FAILURE; HEART PERFORMANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONE RELEASE; HUMAN; ISCHEMIC HEART DISEASE; MICROENVIRONMENT; MYOBLAST; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SCAR; STEM CELL TRANSPLANTATION;

EID: 47249139504     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.4.3.285     Document Type: Review

References (111)

1. Rosamond W, Flegal K, Furie K et al.: Heart Disease and Stroke Statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), E25-E146 (2008).
2. Weir RA, McMurray JJ: Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. Curr. Heart Fall. Rep. 3(4), 175-180 (2006).
3. Orlic D, Hill JM, Arai AE: Stem cells for myocardial regeneration. Circ. Res. 91, 1092-1102 (2002).
4. Chiu RC, Zibaitis A, Kao RL: Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann. Thorac. Surg. 60, 12-18 (1995).
5. Tang YL: Cellular therapy with autologous skeletal myoblasts for ischemic heart disease and heart failure. Methods Mol. Med. 112, 193-204 (2005).
6. Zhang F, Chen Y, Yang Z et al.: Cellular cardiomyoplasty for a patient with heart failure. Cardiovasc. Radiat. Med. 4, 43-46 (2003).
7. Taylor DA, Atkins BZ, Hungspreugs P et al.: Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat. Med. 4, 929-933 (1998).
8. Menasche P: Skeletal myoblasts and cardiac repair. J. Mol. Cell. Cardiol. (2007) (Epub ahead of print).
9. Marelli D, Desrosiers C, el-Alfy M, Kao RL, Chiu RC: Cell transplantation for myocardial repair: an experimental approach. Cell Transplant. 1, 383-390 (1992).
10. Hagege AA, Marolleau JP, Vilquin JT et al.: Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first Phase I cohort of patients. Circulation 114, I108-I113 (2006).
11. Murry CE, Field LJ, Menasche P: Cell-based cardiac repair: reflections at the 10-year point. Cirulation, 112, 3174-3183 (2005).
12. Steendijk P, Smits PC, Valgimigli M, van der Giessen WJ, Onderwater EE, Serruys PW: Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressure - volume loops. Nat. Clin. Pract. Cardiovasc. Med. 3(Suppi. 1), S94-S100 (2006).
13. Reinecke H, Poppa V, Murry CE: Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J. Mol. Cell. Cardiol. 34, 241-249 (2002).
14. Menasche P, Hagege AA, Vilquin JT et al.: Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol. 41, 1078-1083 (2003).
15. Cleland JG, Coletta AP, Abdellah AT et al.: Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF). IMPROVE-CHF, and percutaneous mitral annuloplasty. Eur. J. Heart Fail. 9, 92-97 (2007).
16. Laflamme MA, Gold J, Xu C et al.: Formation of human myocardium in the rat heart from human embryonic stem cells. Am. J. Pathol. 167 (3), 663-671 (2005).
17. 2+ channel blockers. Differentiation 48(3), 173-182 (1991).
18. Banach K, Halbach MD, Hu P, Hescheler J, Egert U: Development of electrical activity in cardiac myocyte aggregatesderived from mouse embryonic stem cells. Am. J. Physiol. Heart Circ. Physiol. 284(6), H2114-H2123 (2003).
19. Kehat I, Khimovich L, Caspi O et al.: Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat. Biotechnol. 22(10), 1282-1289 (2004).
20. Kehat I, Kenyagin-Karsenti D, Snir M et al.: Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 108 (3), 407-414 (2001).
21. 2+ handling and the role of sarcoplasmic reticulum in the contraction. Stem Cells 24(2), 236-245 (2006).
22. Xu C, He JQ, Kamp TJ et al.: Human embryonic stem cell-derived cardiomyocytes can be maintained in defined medium without serum. Stem Cells Dev. 15(6), 931-941 (2006).
23. Binah O, Donilkov K, Sadan O et al.: Functional and development properties of human embryonic stem cells-derived cardiomyocytes. J. Electrocardiol. 40(6 Suppl.), S192-S196 (2007).
24. Kehat I, Kenyagin-Karsenti D, Snir M et al.: Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 108(3), 407-414 (2001).
25. Xue T, Cho HC, Akar FG et al.: Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation 111, 11-20 (2005).
26. Laflamme MA, Chen KY, Naumova AV et al.: Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25(9), 1015-1024 (2007).
27. Mummery C, van der Heyden MA, de Boer TP et al.: Cardiomyocytes from human and mouse embryonic stem cells. Methods Mol. Med. 140, 249-272 (2007).
28. Chachques JC, Trainini JC, Lago N et al.: Myocardial assistance by grafting a new bioartificial upgraded myocardium (MAGNUM clinical trial): one year follow up. Cell Transplant. 16(9), 927-934 (2007).
29. Orlic D, Kajstura J, Chimenti S, Jakoniuk I et al.: Bone marrow cells regenerate infarcted myocardium. Nature 410, 701-705 (2001),
30. Murry CE, Soonpaa MH, Reinecke H et al.: Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428, 664-668 (2004).
31. Song S, Song S, Zhang H, Cuevas J, Sanchez-Ramos J: Comparison of neuron-like cells derived from bone marrow stem cells to those differentiated from adult brain neural stem cells. Stem Cells Dev. 16 (5), 747-756 (2007).
32. Abdel-Latif A, Bolli R, Tleyjeh IM et al.: Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch. Intern. Med. 167(10), 989-997 (2007).
33. Pelacho B, Nakamura Y, Zhang J et al.: Multipotent adult progenitor cell transplantation increases vascularity and improves left ventricular function after myocardial infarction. J. Tissue Eng. Regen. Med. 1(1), 51-59 (2007).
34. Wang JS, Shum-Tim D, Chedrawy E, Chiu RC: The coronary delivery of marrow stromal cells for myocardial regeneration: pathophysiologic and therapeutic implications. J. Thorac. Cardiovasc. Surg. 122(4), 699-705 (2001).
35. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD: Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105(1), 93-98 (2002).
36. Muraski JA, Rota M, Misao Y et al.: Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat. Med. 13(12), 1467-1475 (2007).
37. Makino S, Fukuda K, Miyoshi S et al.: Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest. 103(5), 697-705 (1999).
38. Mangi AA, Noiseux N, Kong D et al.: Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 9, 1195-1201 (2003).
39. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI: Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J. Am. Coll. Cardiol. 46, 1339-1350 (2005).
40. Amado LC, Saliaris AP, Schuler KH et al.: Cardiac repair with myocardial injection of allogenic mesenchymal stem cells after myocardaial infarction. Proc. Nat Acad. Sci. 102, 11474-11479 (2005).
41. Zuk PA, Zhu M, Mizuno H et al.: Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7(2), 211-228 (2001).
42. Zuk PA, Zhu M, Ashjian P et al.: Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 13(12), 4279-4295 (2002).
43. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM: Surface protein characterization of human adipose tissue-derived stromal cells. J. Cell Physiol. 189(1), 54-63 (2001).
44. De Ugarte DA, Morizono K, Elbarbary A et al.: Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 174(3), 101-109 (2003).
45. Traktuev D, Merfeld-Clauss S, Li J et al.: A population of multipotent CD34-positive adiopose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ. Res. 102(1), 77-85 (2008).
46. Yoshimura K, Shigeura T, Matsumoto D et al.: Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J. Cell. Physiol. 208(1), 64-76 (2006).
47. Planat-Benard V, Menard C, Andre M et al.: Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ. Res. 94(2), 223-229 (2004).
48. Bai X, Pinkernell K, Song YH, Nabzdyk C, Reiser J, Alt E: Genetically selected stem cells from human adipose tissue express cardiac markers. Biochem. Biophys. Res. Commun. 353(3), 665-671 (2007).
49. Rehman J, Traktuev D, Li J et al.: Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 109(10), 1292-1298 (2004).
50. Miyahara Y, Nagaya N, Kataoka M et al.: Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat. Med. 12(4), 459-465 (2006).
51. Valina C, Pinkernell K, Song YH et al.: Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur. Heart J. 28(21), 2667-2677 (2007).
52. Watanabe CT, Lee S, Daniels E et al.: Intracoronary adipose tissue-derived stem cell therapy preserves left ventricular function in a porcine infarct model. Am. J. Cardiol. 94(Suppl. 6A), 188E (2004).
53. Alt E, Scharlau M, Pinkernell K et al.: Uncultured, autologous adipose-derived stromal cells - a novel cell source for cardiac repair. Am. J. Card. 96(7 Suppl. I), 71H (2005).
54. Fotuhi P, Song YH, Alt E: Electrophysiological consequence of adipose-derived stem cell transplantation in infarcted porcine myocardium. Europace 9(12), 1218-1221 (2007).
55. Fraser JK, Schreiber R, Strem B et al.: Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes. Nat. Clin. Pract. Cardiovasc. Med. 3(Suppl. 1), S33-S37 (2006).
56. Anversa P, Rota M, Urbanek K et al.: Myocardial aging - a stem cell problem. Basic Res. Cardiol. 100(6), 482-493 (2005).
57. Nishiyama N, Miyoshi S, Hida N et al.: The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro. Stem Cells 25, 2017-2024 (2007).
58. Henning RJ, Abu-Ali H, Balis JU, Morgan MB, Willing AE, Sanberg PR: Human umbilical cord blood mononuclear cells for the treatment of acute myocardial infarction. Cell Transplant. 13(7-8), 729-739 (2004).
59. Wu KH, Zhou B, Yu CT et al.: Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. Ann. Thorac. Surg. 83(4), 1491-1498 (2007).
60. Leri A, Kajstura J, Anversa P: Cardiac stem cells and mechanisms of myocardial regeneration. Physiol. Rev. 85, 1373-1416 (2005).
61. Beltrami AP, Barlucchi L, Torella D et al.: Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114, 763-776 (2003).
62. Oh H, Bradfute SB, Gallardo TD et al.: Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl Acad. Sci, USA 100, 12313-12318 (2003).
63. Dawn B, Stein AB, Urbanek K et al.: Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc. Natl Acad. Sci. USA 102, 3766-3771 (2005).
64. Messina E, De Angelis L, Frati G et al.: Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 95, 911-921 (2004).
65. Barile L, Chimenti I, Gaetani R et al.: Cardiac stem cells: isolation, expansion and experimental use for myocardial regeneration. Nat. Clin. Pract. Cardiovasc. Med. 4(Suppl. 1), S9-S14 (2007).
66. Smith RR, Barile L, Cho HC et al.: Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation, 115, 896-908 (2007).
67. Oyama T, Nagai T, Wada H et al.: Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J. Cell Biol. 176, 329-341 (2007).
68. Hierlihy AM, Seale P, Lobe CG, Rudnicki MA, Megeney LA: The post-natal heart contains a myocardial stem cell population. FEBS Lett. 530, 239-243 (2002).
69. Matsuura K, Nagai T, Nishigaki N et al.: Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J. Biol. Chem. 279, 11384-11391 (2004).
70. + cells clonally. Biochem. Biophys. Res. Commun. 359, 877-883 (2007).
71. + cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433, 647-653 (2005).
72. Mouquet F, Pfister O, Jain M et al.: Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells. Circ. Res. 97, 1090-1097 (2005).
73. Tang YL, Zhao Q, Qin X et al.: Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann. Thorac. Surg. 80, 229-236 (2005).
74. Giordano J, Gerber HP, Williams SP et al.: A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc. Natl Acad. Sci. USA 98, 5780-5785 (2001).
75. Shake JG, Gruber PJ, Baumgartner WA et al.: Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann. Thorac. Surg. 73(6), 1919-1925 (2002).
76. Zhang S, Shpall E, Willerson JT, Yeh ET: Fusion of human hematopoietic progenitor cells and murine cardiomyocytes is mediated by α4 β1 integrin/vascular cell adhesion molecule-1 interaction. Circ. Res. 100, 693-702 (2007).
77. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC: Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428, 668-673 (2004).
78. Tang YL, Zhao Q, Zhang YC et al.: Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul. Pept. 117, 3-10 (2004).
79. Tang YL, Qian K, Zhang YC, Shen L, Phillips MI: Mobilizing of haematopoietic stem cells to ischemic myocardium by plasmid mediated stromal-cell-derived factor-1α (SDF-1α) treatment. Regul. Pept. 125, 1-8 (2005).
80. Sadat S, Gehmert S, Song YH et al.: The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem. Biophys. Res. Commun. 363(3), 674-679 (2007).
81. Zhang FM, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE: Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J. Mol. Cell. Cardiol. 33, 907-992 (2001).
82. Geng YJ: Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure. Science 1010, 687-697 (2003).
83. Niagara NI, Haider HK, Jiang S, Ashraf M: Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ. Res. 100, 545-555 (2007).
84. Phillips MI, Tang YL: Genetic modification of stem cells for transplantation. Adv. Drug Deliv. Rev. 60(2), 160-172 (2008).
85. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927 (1999).
86. Otterbein LE, Choi AM: Heme oxygenase: colors of defense against cellular stress. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L1029-L1037 (2000).
87. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI: Protection from ischemic heart injury by a vigilant heme oxygenase-1 plasmid system. Hypertension 43, 746-751 (2004).
88. Tang YL, Tang Y, Zhang YC et al.: A hypoxia-inducible vigilant vector system for activating therapeutic genes in ischemia. Gene Ther. 12, 1163-1170 (2005).
89. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI: Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J. Am. Coll. Cardiol. 46, 1339-1350 (2005).
90. Vandervelde S, Van Luyn MJ, Tio R, Harmsen MC: Signaling factors in stem cell-mediated repair of infarcted myocardium. J. Mol. Cell. Cardiol. 39, 363-376 (2005).
91. Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson MD: Intracoronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet 363, 783-784 (2004).
92. Askari AT, Unzek S, Popovic ZB et al.: Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362, 697-703 (2003).
93. Grunewald M, Avraham I, Dor Y et al.: VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124, 175-189 (2006).
94. Ceradini DJ, Kulkarni AR, Callaghan MJ et al.: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10, 858-864 (2004).
95. Kucia M, Ratajczak J, Reca R, Janowska-Wieczorek A, Ratajczak MZ: Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during strew and tissue injury. Blood Cells Mol. Dis. 32, 52-57 (2004).
96. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ: Stromal cell-derived factor-1α plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110, 3300-3305 (2004).
97. Yamaguchi J, Kusano KF, Masuo O et al.: Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107, 1322-1328 (2003).
98. Buning H, Braun-Falco M, Hallek M: Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs 177, 139-150 (2004).
99. Dimmeler S, Burchfield J, Zeiher AM: Cell-based therapy of myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 28(2), 208-216 (2007).
100. Lipinski MJ, Biondi-Zoccai GG, Abbate A et al.: Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J. Am. Coll. Cardiol. 50(18), 1761-1767 (2007).
101. Bartunek J, Vanderheyden M, Wijns W et al.: Bone-marrow-derived cells for cardiac stem cell therapy: safe or still under scrutiny? Nat. Clin. Pract. Cardiovasc. Med. 4(Suppl. 1), S100-S105 (2007).
102. Taylor DA, Zenovich AG: Cell therapy for left ventricular remodeling. Curr. Heart Fail. Rep. 4(1), 3-10 (2006).
103. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S: Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J. 28(6), 766-772 (2007).
104. Assmus B, Honold J, Schächinger V et al.: Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 355(12), 1222-1232 (2006).
105. Rosenzweig A: Cardiac cell therapy - mixed results from mixed cells. N. Eng. J. Med. 355(12), 1274-1277 (2006).
106. Schächinger V, Erbs S, Elsässer A et al.: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1210-1221 (2006).
107. Schächinger V, Erbs S, Elsässer A et al.: Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur. Heart J. 27(23), 2775-2783 (2006).
108. Schachinger V, Erbs S, Elsasser A et al.: Sustained clinical benefit from intracoronary infusion of bone marrow derived progenitor cells in patients after acute myocardial infarction. Circulation 116, II777 (2007).
109. Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007).
110. Yu J, Vodyanik MA, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science 21, 318(5858), 1917-1920 (2007).
111. Nakagawa M, Koyanagi M, Tanabe K et al.: Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26(1), 101-106 (2008).